Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
Fusie Lymph&Co, 2,6 miljoen euro extra voor wetenschappelijk onderzoek
feb 2018 | Lymfoom